Insmed Impresses With Study Data - TPIP Could Achieve Peak Revenue of $5.3 Billion and a Market Share of 40%!

Insmed (INSM) is regarded as a specialist in the treatment of rare and severe lung diseases and has already delivered ARIKAYCE, the first and only FDA-approved medication for the treatment of refractory MAC-related lung disease in adults who do not respond to standard therapies. Given the priority FDA review, Brensocatib could also achieve approval in the third quarter as the first approved medication for the treatment of non-cystic fibrosis bronchiectasis (NCFB), potentially reaching an additional 1.25 million patients with a projected peak revenue...